Source: EMA
GAZA – Dozens of Palestinians massacred at US-Israel backed food distribution sites- MSF
Jerusalem: Dozens of Palestinians were killed and hundreds more injured yesterday, 1 June, as they waited for food at the newly created Gaza Humanitarian Foundation distribution centres in Rafah and close to the Netzarim Corridor, according to the Ministry of Health.
Médecins Sans Frontières/Doctors Without Borders (MSF) teams joined the mass casualty response in Nasser hospital, Khan Younis. Patients told MSF they were shot from all sides by drones, helicopters, boats, tanks and Israeli soldiers on the ground.
“Today's events have shown once again that this new system of aid delivery is dehumanising, dangerous and severely ineffective. It has resulted in deaths and injuries of civilians that could have been prevented. Humanitarian aid must be provided only by humanitarian organisations who have the competence and determination to do it safely and effectively,” states Claire Manera, MSF emergency coordinator.
MSF teams at Nasser hospital treated patients with serious injuries today. Some patients in critical condition are still undergoing surgery. But with the blood banks almost empty, medical staff themselves have had to donate blood.
“The hospital corridors were filled with patients, but unlike what I have witnessed before, where most of the patients were women and children, today it was mainly men. They lay in their beds in the hallways because the rooms are already packed with injured people. They had visible gunshot wounds in their limbs, and their clothes were soaked with blood,” says Nour Alsaqa, MSF communications officer. “They looked shattered and distraught after trying to secure food for their children, returning instead injured and empty handed. Outside, there was shouting, sirens, a constant rush of new arrivals to the emergency room. Amid the chaos, we received confirmation that a colleague's brother had been killed while attempting to collect aid from the distribution centre,” she adds. Mansour Sami Abdi, a father of four, described the chaos: “People fought over five pallets. They told us to take food—then they fired from every direction. I ran 200 metres before realising I'd been shot. This isn't aid. It's a lie. Are we supposed to go get food for our kids and die?”
“I was shot at 3:10am. As we were trapped, I bled constantly until 5:00am. There were many other men with me. One of them tried to get me out. He was shot in the head and died on my chest. We had gone there for nothing but food — just to survive, like everyone else,” says Mohammad Daghmeh, 24, a displaced person in Al-Qarara, Khan Younis.
This is the second time this new system of aid distribution has led to bloodshed. On 27 May, the first afternoon of distribution in Rafah, Israeli forces shot dozens of people as wholly insufficient amounts of basic lifesaving supplies were distributed amid chaos.
As a result of the total siege that was imposed by the Israeli authorities on 2 March, 100 per cent of Gaza is now at risk of famine, according to the United Nations. Since 19 May, the few hundred food trucks brought in – an insufficient fraction of what is needed – have spread despair among the 2 million plus people who have been largely deprived of food, water, and medication for three months now. Totally or partially blocking humanitarian aid to enter Gaza has aggravated the situation of all Gazans.
MSF reinforces that, along with displacement orders and bombing campaigns that kill civilians, weaponising aid in this manner may constitute crimes against humanity. Only a lasting ceasefire and the immediate opening of Gaza's borders for humanitarian aid – including food, medical supplies, fuel and equipment – can ease this man-made catastrophe.
Rising dairy prices lift export prices – Stats NZ media and information release: International trade: March 2025 quarter

Rising dairy prices lift export prices – media release
3 June 2025
Export prices rose 7.1 percent in the March 2025 quarter, led by dairy prices, according to figures released by Stats NZ today.
“Export prices have been increasing since March 2024 and are now 17 percent higher than they were a year ago,” international accounts spokesperson Viki Ward said.
Prices for dairy products (New Zealand’s top export commodity) rose 10 percent, led by a 13 percent increase in milk powder prices compared with the December 2024 quarter.
“The increase in dairy prices was shared across all of the major dairy categories,” Ward said.
Visit our website to read this news story and information release and to download CSV files:
- Rising dairy prices lift export prices
- International trade: March 2025 quarter
- CSV files for download
Farmer satisfaction with banks better – but fragile
Source: Federated Farmers
Culture – Pushing the boundaries of creativity in kapa haka
Source: Rata Foundation
Banking – Kiwibank first New Zealand bank to partner with Kiwi tech company Wych to provide open banking – and draws line with zero fees
Source: Kiwibank
- Local tech company, Wych, will assist Kiwibank in implementing open banking.
- Kiwibank will not be charging accredited third parties to make standard API requests.
- Open banking will deliver more value, choice and flexibility for customers.
Kiwibank is the first New Zealand bank to partner with Wych, a New Zealand based financial technology company specialising in providing open data services and capabilities to data holders and data recipients.
Wych will provide the integration capability to connect accredited third parties with Kiwibank as it delivers open banking.
Steve Jurkovich, Kiwibank’s Chief Executive, says, “As a modern integration provider, Wych’s solution is cloud hosted and provided as a complete end-to-end SaaS solution. It’s also scalable and will enable Kiwibank to easily adapt as the open banking ecosystem develops.
“This next step in our open banking journey will set us up to collaborate with even more innovative partners to offer services and experiences that provide our customers greater value and choice. As a smaller player compared to the larger banks, Kiwibank is excited to partner with fintechs to drive more competition to make Kiwi better off.”
Dermot Butterfield, Wych’s Chief Executive Officer, says, “We are excited to be partnering with Kiwibank to build on the opportunity that open banking represents for their customers, including more innovation and customer-centric solutions as the market matures.”
Kiwibank is proud to be supporting a Kiwi technology company and leveraging the expertise we have right here in New Zealand.
Kiwibank takes competitive stand on open banking fees
Kiwibank exists to challenge the status quo and to create a future where banking in New Zealand is stronger and fairer than ever before.
“We see the significant value open banking can deliver for our customers and we want to enable that,” says Jurkovich. “That’s why we won’t be charging accredited third parties to make standard API requests.”
This sets Kiwibank apart. While some banks are offering temporary waivers on fees charged to accredited third parties, in the longer term those costs could be passed on to customers.
“At Kiwibank, we’re committed to shaping an open banking environment that delivers real benefits for New Zealanders,” says Jurkovich. “By removing cost barriers we’re helping to unlock innovation that puts customers first – enabling more tailored, transparent, and empowering financial experiences.”
Kiwibank is committed to delivering payment initiation API services by 30 May 2026 and account information API services by 30 November 2026.
About Kiwibank
Kiwibank is a Purpose-led organisation that has modern, Kiwi values at heart and keeps Kiwi money where it belongs – right here in New Zealand. As a Kiwi bank, with more than a million customers, our trusted experts are focused on supporting Kiwi with their home ownership aspirations and backing local business ambitions, so together we can thrive here in Aotearoa and on the world stage. Kiwibank is the #1 bank in Kantar’s 2024 Corporate Reputation Index and the only bank in the top 20. To find out more about Kiwibank visit www.kiwibank.co.nz.
Fire Safety – Kiwis return from assisting with the New South Wales floods
Source: Fire and Emergency New Zealand
Health – From Today Eligible People with Stage III Melanoma Can Access Funded KEYTRUDA® (pembrolizumab)
Auckland, New Zealand, 1 June 2025 – MSD (tradename of Merck & Co., Inc., Rahway, N.J., USA (NYSE: MRK) is delighted to announce that from today, Pharmac will widen the funding of the immunotherapy cancer medicine KEYTRUDA® (pembrolizumab) to include the treatment of eligible people with stage III melanoma. 1
Vanessa Gascoigne, Merck Sharp & Dohme (New Zealand) Limited (MSD) Director, expressed her excitement, stating; “Funded access to KEYTRUDA has been available in New Zealand for certain people with advanced melanoma since 2016. 2
“We are thrilled that Pharmac has widened its funding of KEYTRUDA from today, to include eligible people with stage III melanoma. 1
“This marks the first time KEYTRUDA will be funded by Pharmac for the treatment of a cancer before it has progressed to an advanced stage. 1,3
“Thanks to the Government’s increase in the medicines budget last year, and National’s Cancer Policy, additional people living with cancer will now receive funded access to KEYTRUDA.” 1, 4, 5
New Zealand has one of the highest melanoma rates in the world; therefore preventing, and detecting melanoma early, must be absolute priorities. 6
KEYTRUDA is an immunotherapy cancer medicine registered for 31 indications and is now publicly funded for 12 of these indications.7,1 MSD will continue to work with the funding agency Pharmac, to try and obtain funded access for more people with cancer.
Ms Gascoigne says, “Faster funded access to cancer treatment may benefit people across New Zealand and we believe patients should have access to KEYTRUDA where clinical evidence exists, ensuring fair and equitable access.”
KEYTRUDA® (pembrolizumab) is available as a 100 mg/4 mL concentrate for solution for infusion.
The KEYTRUDA Consumer Medicine Information (CMI) is available at www.medsafe.govt.nz.
KEYTRUDA is a Prescription Medicine and may be used in adults:
· After surgery to remove melanoma, non-small cell lung cancer or renal cell carcinoma to help prevent the cancer from coming back
· Before surgery to treat triple-negative breast cancer and then continued after surgery to help prevent the cancer from coming back
· To treat bladder cancer which has not spread to nearby tissues but is at high-risk of spreading and where bladder removal is not preferred
· To treat certain patients with the following types of advanced cancers:
o Melanoma
o Non-small cell lung cancer
o Malignant pleural mesothelioma (MPM)
o Classical Hodgkin Lymphoma (cHL)
o Urothelial carcinoma
o Head and neck squamous cell carcinoma
o Renal cell carcinoma
o Gastric or gastroesophageal junction adenocarcinoma
o Oesophageal carcinoma
o Cutaneous squamous cell carcinoma.
o Cervical cancer
o Endometrial carcinoma
o Triple-negative breast cancer
o A kind of cancer that can occur in any part of the body and is shown by a laboratory test to be microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR)
o Colon or rectal cancer that is shown by a laboratory test to be MSI-H or dMMR
o Merkel cell carcinoma (MCC)
o Biliary tract carcinoma
KEYTRUDA may be used in children with MPM, cHL, MCC, MSI-H or dMMR cancer, or after surgery to remove melanoma. It is not known if KEYTRUDA is safe and effective in children with MSI-H or dMMR cancer of the brain or spinal cord (central nervous system cancers).
You should not be given KEYTRUDA if you are allergic to pembrolizumab or to any of the other ingredients listed at the end of the CMI.
KEYTRUDA can cause harm or death to unborn babies. Talk to your doctor if you are a woman who could become pregnant and use effective contraception while you are being treated with KEYTRUDA and for at least 4 months after the last dose of KEYTRUDA. Do not breastfeed while taking KEYTRUDA.
Serious immune-mediated side effects have occurred affecting the lungs, intestines, liver, kidneys, hormone glands, blood sugar levels, skin, other organs and in transplant recipients. Some of these side effects can sometimes become life-threatening and can lead to death. These side effects may happen anytime during treatment or even after your treatment has ended and you may experience more than one side effect at the same time. Serious infusion reactions have also occurred.
Very common side effects with KEYTRUDA alone include diarrhoea, nausea, itching, rash, joint pain, back pain, feeling tired, cough, patches of discoloured skin, stomach pain, decreased levels of sodium in blood and low levels of thyroid hormone.
When KEYTRUDA was given in combination with chemotherapy, hair loss, vomiting, decreased white-blood cell count, mouth sores, fever, decreased appetite, decreased number of red blood cells, decreased number of platelets in the blood and swelling of the lining of the digestive system (for example mouth, intestines) were also commonly reported.
When KEYTRUDA was given in combination with axitinib, high blood pressure, fatigue, low levels of thyroid hormone, decreased appetite, blisters or rash on palms of your hands and soles of your feet, increased liver enzyme levels, hoarseness, and constipation were also commonly reported.
When KEYTRUDA was given in combination with lenvatinib, high blood pressure, decreased appetite, low levels of thyroid hormone, vomiting, weight loss, headache, constipation, hoarseness, urinary tract infection, stomach-area (abdominal pain), blisters or rash on the palms of your hands and soles of your feet, protein in your urine, increased liver enzyme levels and feeling weak were also commonly reported.
The most common side effects when KEYTRUDA is given alone to children include fever, vomiting, headache, stomach pain, decreased number of red blood cells, cough, and constipation. (v56)
KEYTRUDA has risks and benefits. Talk to your doctor to see if KEYTRUDA is right for you. If symptoms continue or you have side effects, tell your doctor.
KEYTRUDA is funded to treat certain patients with the following types of advanced cancers: melanoma, non-small cell lung cancer, MSI-H or dMMR colorectal cancer, triple-negative breast cancer, head and neck squamous cell carcinoma, urothelial carcinoma, and classical Hodgkin lymphoma. KEYTRUDA is also funded for certain patients with Stage IIIB-D melanoma. Patients must meet specific criteria for funding.
KEYTRUDA is not funded for the treatment of all other cancers <listed above>, which means you will need to pay for the full cost of the medicine and its administration. Ask your doctor about the cost of the medicine and any other medical fees that may apply.
Merck Sharp & Dohme (New Zealand) Limited. Level 3, 123 Carlton Gore Road, Newmarket, Auckland.
Copyright © 2025 Merck & Co., Inc., Rahway, NJ, USA, and its affiliates. All rights reserved.
About MSD
At MSD, known as Merck & Co., Inc., Rahway, N.J., USA in the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit www.msd.com
Copyright © 2025 Merck & Co., Inc., Rahway, NJ, USA, and its affiliates. All rights reserved.
Merck Sharp & Dohme (New Zealand) Limited. Level 3, 123 Carlton Gore Road, Newmarket, Auckland. NZ-NZ-KEY-00984 V1.0 NP22833 June 2025
References
1. Pharmac Community Schedule: Pembrolizumab Special Authority Form SA2491 June 2025. Available at https://schedule.pharmac.govt.nz/2025/06/01/SA2491.pdf Accessed May 2025
2. Pharmac. News and resources. Decision regarding funding of pembrolizumab (Keytruda), nivolumab (Opdivo), posaconazole (Noxafil) and raltegravir (Isentress) Available at:
3. Pharmac Community Schedule: Pembrolizumab Special Authority Form SA2386 May2025. Accessed May 2025
4. Pharmac. News and resources. Update on new medicines funding after the budget uplift. Available at:
https://www.pharmac.govt.nz/news-and-resources/news/update-on-new-medicines-funding-after-the-budget-uplift Accessed May 2025
5. National Party. Policies. Helping More Kiwis Fight Cancer. Available at:
https://assets.national.org.nz/Plan_Helping_More_Kiwis_Fight_Cancer.pdf Accessed May 2025
6. MelNet: Skin Cancer Prevention and Early Detection Strategy 2024 – 2028. Available athttps://strategy.melnet.org.nz/ Accessed May 2025
7.KEYTRUDA Data Sheet. Available at: https://www.medsafe.govt.nz/profs/Datasheet/k/Keytruda.pdf Accessed May 2025
Fire and Emergency King’s Birthday honours recipients congratulated
Source: Fire and Emergency New Zealand
- Ronald (Ron) Ealam (Oxford) – Member of the New Zealand Order of Merit (MNZM) for services to Search and Rescue
- Marius Bron (Fox Glacier) – King’s Service Medal (KSM) for services to Search and Rescue and the community
- Gavin Dennis (Matatā) – King’s Service Medal (KSM) for services to Fire and Emergency New Zealand and the community
- Alan (Curly) Troon (Taihape) – King’s Service Medal (KSM) for services to Fire and Emergency New Zealand.
